Indaptus Therapeutics Inc (INDP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $422.38M
Last updated: Nov 17, 2026 at 4:41 PM ET
Indaptus Therapeutics Inc (INDP) Stock Chart
Indaptus Therapeutics (INDP) has a latest price of $3.32 on Nov 17, 2026, 44.3% below its 52-week high of $5.96. Its price rose 32.3% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 56.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $20,056.02 in Sep 2017 and its lowest $1.15 in Aug 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart INDP with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for INDP.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 253.2%, and over 6 months it rose 149.6%. The month-end price fell 95.2% over the 3 years through Oct 2026, a compound annual decline of 63.8%.
| Period | Change |
|---|---|
| 1 month | +21.6% |
| 3 months | +253.2% |
| 6 months | +149.6% |
| 12 months | +32.3% |
| 12 months, with dividends | +32.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -95.2% | -63.8% |
| 5 years | -98.5% | -56.6% |
| 10 years | -100.0% | -56.1% |
Price by Year
Its best calendar year was 2018, when the price rose 46.4%, and its weakest was 2019, when it fell 93.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.09 | +6.2% |
| 2025 | $2.91 | -87.7% |
| 2024 | $23.59 | -52.2% |
| 2023 | $49.30 | +21.4% |
| 2022 | $40.62 | -74.6% |
| 2021 | $159.66 | -58.7% |
| 2020 | $386.55 | -65.5% |
| 2019 | $1,120.45 | -93.4% |
| 2018 | $16,896.36 | +46.4% |
| 2017 | $11,540.62 | -9.6% |
Trading Range
The price is 9.5% above its 50-day average of $3.03 and 42.6% above its 200-day average of $2.33.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.32 | |
| 52-week high | $5.96 | -44.3% |
| 52-week low | $0.92 | +260.9% |
| 50-day average | $3.03 | +9.5% |
| 200-day average | $2.33 | +42.6% |
Price Risk
Over 3 years, its largest fall from a peak was 98.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.59 |
| Largest fall, 1 year | -80.3% |
| Largest fall, 3 years | -98.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About INDP
What is INDP's 1-year price change?
Indaptus Therapeutics's price rose 32.3% over the past 12 months. With dividends included, the 12-month total return was 32.3%.
What is INDP's 5-year price change?
Indaptus Therapeutics's month-end price fell 98.5% over the 5 years through Oct 2026, a compound annual decline of 56.6%. These figures leave out dividends.
What is INDP's 52-week high and low?
Indaptus Therapeutics's 52-week high is $5.96 and its 52-week low is $0.92. Its latest price of $3.32 on Nov 17, 2026 is 44.3% below the high.
What is INDP's beta?
Indaptus Therapeutics's 1-year beta against the S&P 500 is 1.59, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 80.3%.
Is the INDP chart free?
Yes. Advanced Charting for INDP is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
INDP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors